Belzutifan Approved for Advanced Renal Cell Carcinoma Belzutifan Approved for Advanced Renal Cell Carcinoma

The FDA approval makes belzutifan the first agent specifically indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news